USA flag logo/image

An Official Website of the United States Government

Long-acting VIP formulations for the treatment of chronic inflammatory diseases

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93398
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
AI082723
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
PHARMAIN CORPORATION
19805 N. Creek Pkwy, Suite 200 Bothell, WA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: Long-acting VIP formulations for the treatment of chronic inflammatory diseases
Agency: HHS
Contract: 1R43AI082723-01
Award Amount: $600,000.00
 

Abstract:

DESCRIPTION (provided by applicant): Despite the success of TNF-inhibitors and other new biological drugs for the treatment of autoimmune and other chronic inflammatory diseases, there are still many patients that are only poorly controlled. Vasoactive int estinal peptide (VIP) is an immunomodulatory peptide that induces regulatory T-cells and anti-inflammatory cytokine responses and has shown efficacy in numerous rodent models of autoimmune diseases with predominant TH1-type immune responses. Use of VIP in humans is severely hindered by its short in vivo half-life, and the therapeutic window is limited by the vasodilatory properties of this peptide that can cause an unsafe drop in blood pressure upon injection. Formulating VIP into a nanocarrier can improve both properties as the binding to the nanocarrier sequesters it from degrading enzymes and excretion by the kidney. The binding of VIP to a nanocarrier also decreases the concentration of free VIP in serum, thereby decreasing the blood pressure drop and in creasing the therapeutic window. In this application two different nanocarriers will be compared in their ability to formulate VIP for the treatment of chronic inflammatory diseases. The nanocarriers are a Protected Graft Copolymer (PGC), in which a poly-l ysine backbone is grafted with polyethylene glycol (PEG) side chains. The load-molecule will bind to specific residues between the PEG-side chains. The other nanocarrier consists of a sterically stabilized micelle (SSM). These different nanocarrier-VIP for mulations will be compared in terms of efficacy in collagen induced arthritis, a mouse model of rheumatoid arthritis. Additionally, the pharmacokinetics of the different nanocarrier-VIP formulations will be determined. Toxicity will be tested using non-inv asive blood pressure monitors that measure peripheral arterial pressure in the tail with an inflatable tail cuff, in addition to monitoring general parameters of health (behavior, appearance, diarrhea etc). PUBLIC HEALTH RELEVANCE: Vasoactive intest inal peptide (VIP) is a hormone in the human body that can be used for the treatment of autoimmune diseases in animal models. Rapid degradation and side effects at high dose have so far limited VIP use in humans. In this project VIP will be formulated into forms that will deal with these problems that will allow its universal use in many human diseases.

Principal Investigator:

Sandra Reichstetter
2065681494
SREICHSTETTER@PHARMAIN.COM

Business Contact:

Elijah M. Bolotin
ebolotin@pharmain.com
Small Business Information at Submission:

PHARMAIN CORPORATION
720 BROADWAY, STE 511 SEATTLE, WA 98122

EIN/Tax ID: 364357862
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No